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Abstract
Background: The antimalarial activity of plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone), a naturally occurring
naphthoquinone widely distributed in the Plumbaginaceae family has previously been demonstrated in vitro (good
activity) and in vivo (weak activity). The aim of the study was to investigate the pharmacokinetic profile following a
single oral dosing to explain inconsistency of results of the in vitro and in vivo antimalarial activities. In addition,
toxicity profiles and potential of modulation of cytochrome P450 enzymes (CYP1A2 and CYP3A11) were also
investigated.
Methods: The pharmacokinetics and toxicity of plumbagin were investigated in rats. The propensity of plumbagin
to modulate the mRNA expression and activities of the two inducible forms of hepatic drug metabolizing enzyme
cytochrome P450 (CYP450), i.e., CYP1A2 and CYP3A11, was investigated using microsomes prepared from mouse
livers.
Results: Acute and subacute toxicity tests indicate low toxicity of plumbagin with maximum tolerated doses of 150
(single oral dose) and 25 (daily doses for 28 days) mg/kg body weight, respectively. The pharmacokinetic profile of
plumbagin following a single oral dose of 100 mg/kg body weight suggests that delayed absorption and short
residence time (median values of time to maximal concentration and elimination half-life = 9.63 and 5.0 h,
respectively) in plasma. Plumbagin did not modulate mRNA expression and activities of CYP1A2 and CYP3A11.
Conclusions: Plumbagin was well tolerated following oral dose administration in rats. Pharmacokinetic property of
this compound may be a limiting factor that explains the weak antimalarial activity of plumbagin observed in
animal models. Potential metabolic interaction with co-administered drugs that are metabolized by CYP1A2 or
CYP3A11 are unlikely.
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Background
Chemotherapy remains the mainstay for malaria control
in the absence of a suitable vaccine treatment. Natural
products including medicinal plants have been well
demonstrated as promising sources of effective antimal-
arial drugs [1]. Plumbagin (5-hydroxy-2-methyl-1,4-
naphthoquinone, a naturally occurring naphthoquinone
widely distributed in the Plumbaginaceae family, has
been reported to possess a wide spectrum of biological
and pharmacological properties including activities
against malaria, leishmania and trypanosome parasites,
as well as against virus, cancers, and bacteria [2]. Prom-
ising antimalarial activities of both plumbagin and the
crude ethanolic extract of Plumbago indica Linn. (root)
have been demonstrated in vitro and in vivo [3, 4]. In
the in vitro model, the extract exhibited good to moder-
ate antimalarial activity (class III antimalarial activity)
with IC50 (concentration producing 50 % growth inhib-
ition) of 3 and 6.2 μg/mL, against K1 chloroquine-
resistant and 3D7 chloroquine-sensitive P. falciparum
clones, respectively [3]. Based on its relatively high se-
lectivity index (SI = 44.7 and 21.6, respectively), it ap-
pears to be safe for human used for treatment of
malaria. The active constituent plumbagin also shows
promising antimalarial activity with median IC50 values
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against K1 and 3D7 P. falciparum clones of 370 and 580
nM, respectively. The mean IC50 values of the standard
antimalarial drugs artesunate, mefloquine, quinine and
chloroquine against K1 and 3D7 P. falciparum clones
are 1.5 vs. 2 nM, 12 vs. 10 nM, 133- vs. 52 nM and 130
vs. 8 nM, respectively [5]. The activity against P. falcip-
arum enzyme succinate dehydrogenanse (SDH) includ-
ing parasite growth has been shown to be inhibited to
50 % by plumbagin at inhibitory concentrations of 5 and
0.27 mM, respectively [6]. In the in vivo model, plumba-
gin at the dose of 25 mg/kg body weight given for 4 days
however, exhibited only weak to antimalarial activity
with regard to the inhibitory activity on the reduction of
parasitemia and the prolongation of survival time [4].
The inconsistencies of the observed antimalarial activity
of plumbagin in the in vitro and in vivo models have been
partly clarified in the following series of investigation with
particular attention on the pharmacokinetic factor. Perme-
ability of the compound across the human colon epithelial
cell monolayer Caco-2 has been shown to be moderate and
the transport mechanism is likely to be a passive transport
[7]. With the application of single-photon emission com-
puted tomography/computed tomography (SPECT/CT)
imaging system and radiochemical analysis, blood kinetics
and tissue distribution of radiolabeled plumbagin (99mTech-
netium-plumbagin complex) was investigated in healthy
and P. berghei-infected mice [8]. The labeled complex dis-
tributed to all organs of both healthy and infected mice but
with high intensity in liver, followed by lung, stomach, large
intestine, and kidney. Accumulation in spleen was markedly
noticeable in the infected mice. Plumbagin-labeled complex
was rapidly cleared from blood with short elimination half-
life of about 2–3 h and major routes of excretion were
hepatobiliary and pulmonary routes. Altogether, these pre-
liminary observations may suggest limited pharmacokinetic
properties of plumbagin which result in inadequate sys-
temic drug circulation. Furthermore, results of our previous
studies show that both plumbagin and the crude extract of
P. indica Linn. are relatively potent inhibitors of CYP450
[9, 10] and this is of concern for the potential herb-drug in-
teractions when plumbagin or the extract containing plum-
bagin is to be co-administered with conventional drugs.
The aim of the present study was to further investigate
the pharmacokinetics and toxicity of plumbagin using trad-
itional pharmacokinetic study in rat model. In addition, we
also investigated propensity of plumbagin to modulate
mRNA expression and activities of the two inducible forms
of hepatic drug metabolizing enzyme cytochrome P450
(CYP450), i.e., CYP1A2 and CYP3A11 in mice.
Methods
Chemicals
The authentic plumbagin (purity 98.2 %) was obtained
from Apin chemicals Co. Ltd. (OX, UK). Tween-80,
phenacetin, paracetamol, caffeine, omeprazole, 5-
hydroxyomeprazole, nifedipine, oxidized nifedipine, ke-
toconazole, nootkatone, α-napthoflavone, and diazepam
were purchased from Sigma-Aldrich (St. Louis, MO,
USA). 1,4-Naphthoquinone was purchased from Wako
Pure Chemical Industries, Co. Ltd. (Osaka, Japan). β-
Nicotinamide adenine dinucleotide phosphate (reduced
form) tetrasodium salt (NADPH) was purchased from
Merck KGaA (Darmstadt, Germany). Pooled human
liver microsomes (from 50 donors) were obtained from
Gibco BRL Life Technologies (Grand Island, NY, USA).
TRIzolTM reagent, SuperScript™ III Reverse Transcript-
ase kit, and SYBR Green Real-Time PCR Master Mixes
were purchased from Invitrogen Life Technologies Inc.
(Carlsbad, CA, USA). RQ1 RNase-Free DNase was pur-
chased from Promega (Mannheim, Germany). MS grade
water, methanol and acetonitrile were purchased from
Yes-sci Co., Ltd. Isoflurane was purchased from Wako
Pure Chemical Industries, Co. Ltd. (Osaka, Japan).
Animals
Wistar rats (5 weeks of ages, weighting 200–210 g) of
both genders were used for toxicity testing and pharma-
cokinetic investigation. Male ICR (Imprinting Control
Region) mice (5 weeks of age, weighting 20–25 g) were
used for investigation of the modulatory effect of plum-
bagin on CYP1A2 and CYP3A11. All animals were ob-
tained from the National Laboratory Animal Centre,
Thailand. Animal experiments were carried out in ac-
cordance with the Guidelines for the Care and Use of
Laboratory Animals. They were housed under controlled
light (12 h light and 12 h dark) and temperature (25 °C)
in the animal house facility at Thammasat University.
All were fed with a stock diet and water ad libitum. Ap-
proval of the study protocol was obtained from the Eth-
ics Committee for Animal Research, Thammasat
University, Thailand (certification number 005/2558).
Toxicity testing
Plumbagin was dissolved with 20 % Tween-80 to obtain
the desired concentrations. Wistar rats were fasting 2 h
before administration of a single oral dose of the plum-
bagin. Animals were divided into eight groups of six (3
males and 3 females for each group). For the acute tox-
icity test, rats in each group were fed with plumbagin at
a single oral dose of 500, 250, or 150 mg/kg body weight
(1 mL); control group received a single oral dose of 20 %
Tween-80 (1 mL). For the subacute toxicity test, rats in
each group were fed with plumbagin at a daily dose of
100, 50, or 25 mg/kg body weight (1 mL) for 28 days;
control group received a daily oral dose of 20 % Tween-
80 for 28 days (1 mL).
General behavioral changes of each rat was observed
continuously for 1 h after each dose, intermittently every
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4 h, and thereafter over a period of 24 h [11, 12]. Ani-
mals were observed for up to 14 days for acute toxicity
test and 28 days for subacute toxicity test, for any sign
of toxicity (behavioral change related to central nervous,
cardiovascular and gastrointestinal systems, body weight
change, and water and food consumption). At the end of
the observation period, all animals were sacrificed
under ether anesthesia (isoflurane) and vital organs
(liver, lung, kidney, heart, and spleen) were removed
from all animals for gross and histopathological
examination. Blood sample was collected from each
rat through cardiac puncture for analysis of plasma
chemistry (heparin as an anticoagulant) and blood
hematology (EDTA as an anticoagulant).
Pharmacokinetic study
Pharmacokinetic investigation was performed in 4 male
Wistar rats (weighing 200–350 g) following a single oral
dose of 100 mg/kg body weight plumbagin (1 mL). The
control group received 20 % Tween-80 (1 mL). Blood
samples (500 μL each) were collected from the tail vein
of each rat at 0, 1, 2, 3, 5, 8, 24, 48, and 72 h after dos-
ing. Plasma was separated from whole blood samples
through centrifugation at 3000 × g for 10 min.
Concentrations of plumbagin in plasma and urine
samples collected from all animals were measured using
liquid chromatographic-mass spectrometry (LC-MS/MS)
according to the previously described method with mod-
ifications [13]. The limits of quantification (LOQ) and
detection (LOD) for plumbagin were 5 and 2 ng/mL
plasma, respectively. Recovery of the compound in
plasma after sample preparation procedure was between
82 and 92 %. The assay intra- and inter-day coefficients
of variation (% CV) were 0.7–4.7 % and 3.9–8.3 %, re-
spectively. In brief, plasma sample (100 μL) was mixed
with 10 ng/mL honokiol (5 μL) and ethyl acetate (1 mL)
and centrifuged at 12,000 × g for 15 min. The upper
layer was transferred to a new tube and evaporated to
dryness under nitrogen flow. The dried residue was
reconstituted with 100 μL of the mobile phase and a
5 μL aliquot was injected onto the LC–MS/MS. The
samples were collected from the metabolic cages at
24, 48, 72, 96, and 120 h. All were centrifuged at
1500 × g for 10 min and the supernatant (100 μL)
was extracted with ethyl acetate (1 mL). The extract
was dried and the residue was reconstituted with
100 μL of the mobile phase and a 5 μL aliquot was
injected onto the LC–MS/MS.
The LC-MS/MS system used consists of Agilent 1100
Separation Module (Agilent Technologies, CA, USA)
solvent and sample delivery, Av QTRAP 5500 Triple
Quadrupole Mass Spectrometer (AB Sciex, Foster City,
CA, USA) equipped with CID, and Multiple Reactions
Monitoring (MRM). Mass spectrometric analysis was
performed in the negative-ion mode (ESI). The following
parameters of the turbo ion spray were used: ion spray
voltage = −4500 V; the ion source gas 1 (GS1), gas 2
(GS2), curtain gas (CUR) and collision gas (CAD) were
50, 60, 25 and 5, respectively; and the desolvation gas
(nitrogen) heated to 500 °C. Separation was performed
using Hypersil gold reversed-phase C18 column
(50 mm × 4.6 mm i.d., 5 μM: Thermo Scientific, Fre-
mont, CA, USA) with the mobile phase consisting of a
mixture of (A) water containing 0.1 % formic acid and
(B) 100 % methanol, running with gradient mode at the
flow rate of 0.6 mL/min at 25 °C (Table 1). On the basic
of the full-scan mass spectra of each analyze, the most
abundant ions were selected and the mass spectrometer
was set to monitor the transitions of the precursors to
the product ions as follows: m/z 187– >159 for plumba-
gin, and 265– >224 for honokiol (internal standard). The
system was controlled by AnalystTM software (AB Sciex,
Foster City, CA, USA).
Pharmacokinetic parameters were determined using a
non-compartmental analysis using WinNonLinTM soft-
ware (version 6.3, Pharsights, Certara, USA). Concentra-
tions of drugs lower than the limit of quantification
(LOQ) were expressed as zero (undetectable). The Cmax
(maximum concentration); tmax (time of maximum con-
centration) were determined by direct inspection of the
plasma concentration–time data. AUC (area under the
concentration–time curve) from time 0 to 48 (AUC0-
48h), and total AUC (AUC0−∞) were calculated using the
trapezoidal rule. The extrapolated AUC from the last
sampling time to infinity was estimated from Ct/elimin-
ation rate constant (λz). λz was calculated from at least
five concentration–time points of elimination phase. Ap-
parent oral clearance (CL/F) was calculated as dose/
AUC0−∞. Volume of distribution (Vz/F) was calculated as
CL/F/z, and the terminal half-life (t1/2z) was calculated
as 0.693/λz. Mean residence time (MRT) was calculated
from the ratio of AUMC0-α)/AUC0−∞.
Modulation of CYP450 activity
Mice were divided into four groups (3 male mice each).
Mice in the treated groups were fed with plumbagin at a
daily oral dose of 25, 12.5, or 6.25 mg/kg body weight
Table 1 HPLC condition for quantitative analysis plumbagin
using gradient mobile phase consisting of (A) water containing
0.1 % formic acid and (B) 100 % methanol
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(1 mL) for 28 days. The control group received a daily
oral dose (1 mL) of 20 % Tween-80 for 28 days. At the
end of the experiment period, all animals were sacrificed
under ether anesthesia and livers were removed for in-
vestigation of the modulatory effect of plumbagin on
hepatic CYP1A2 and CYP3A11.
Effect of plumbagin on CYP1A2 and CYP3A11 activities
The liver samples were rinsed with ice-cold, 0.9 %NaCl,
homogenized in 50 mM sodium phosphate buffer
(pH 7.4) containing 0.1 mM EDTA, and centrifuged at
9000 × g for 20 min. The supernatant was ultracentri-
fuged at 105,000 × g for 60 min, and the resulting micro-
somal pellets were suspended with ice cold 1.15 % KCl
solution and ultracentrifuged at 105,000 × g for 60 min.
The pellets were homogenized with 50 mM potassium
phosphate (pH 7.4) containing 0.1 mM EDTA and 10 %
glycerol. Protein concentrations were determined by
Bradford protein assay [14] and the suspended micro-
somes were aliquoted and stored at −80 °C until use.
Phenacetin O-deethylation and nifedipine oxidation
were used as selective markers for CYP1A2 and
CYP3A11 activities, respectively [10]. The substrate con-
centration equivalent to the apparent Km (Michaelis-
Menten constant) of each individual CYP450 was used
in the experiment. Final concentration of organic solvent
in the incubation mixture was less than 1 %. The incuba-
tion conditions for determination enzyme activity to
both CYP450 isoforms were according to the previously
described methods [15–18].
The incubation mixture of 500 μL containing the se-
lective substrate (20 μM phenacetin and 40 μm nifedi-
pine for CYP1A2 and CYP3A11, respectively), mice liver
microsomes (in 100 mM phosphate buffer pH 7.4) was
pre-incubated at 37 °C for 5 min in a shaking water bath.
The reaction was initiated by the addition of NADPH
and further incubated for the specified periods. The in-
cubation time (60 and 40 min for phenacetin O-deethy-
lation and nifedipine oxidation, respectively) and protein
concentration (0.3 mg/mL for both reactions) used were
within the linear range for respective CYP450 activity.
Each experiment was performed in triplicate. CYP1A2-
mediated phenacetin O-deethylation and CYP3A11-
mediated nifedipine oxidation reactions were terminated
by the addition of 500 μL of cold acetonitrile. The in-
ternal standard (50 μL) caffeine (for CYP1A2) or diaze-
pam (for CYP3A11) was added. Concentrations of
paracetamol (metabolite of CYP1A2) and oxidized ni-
fedipine (metabolite of CYP3A11) in the incubation mix-
tures were determined using HPLC with UV detection
[8]. HPLC analysis was performed with HPLC system
consisting of Spectra System HPLC with P4000 solvent
delivery system, equipped with an AS3000 auto sampler,
UV1000 detector, SN4000 controller (Thermo Finnigan,
San Jose, CA, USA), and Chrome Quest software (ver-
sion 4.0). Twenty microliters of each sample was
injected onto the HPLC column for analysis. HPLC con-
dition for determination of paracetamol consisted of C-
18 reversed phase column (Thermo Hypersil Gold,
210 × 4.6 mm, 5 μm particle size), gradient mobile phase
(a mixture of acetonitrile and distilled water) with an ini-
tial ratio of 10:90 at the flow rate of 1 mL/min, and UV
detection at 240 nm. The calibration curve was prepared
at the concentration range of 1–50 μM. HPLC condition
for determination of oxidized nifedipine consisted of C-
18 reversed phase column (Thermo Hypersil Gold,
210 × 4.6 mm, 5 μm particle size), mobile phase (a mix-
ture of methanol and water at the ratio of 65:35 % v/v)
with a flow rate of 1.0 mL/min, and UV detection at
270 nm. The calibration curve was prepared at the con-
centration range of 1–25 μM. The linearity of the cali-
bration curve for each analytical assay for the CYP-
mediated production of metabolite was demonstrated
with the determination coefficient (r2) of greater than
0.995. Quality control (QC) samples were run in dupli-
cate in each analytical batch at low, medium, and high
concentrations. The criteria for acceptability was four
out of six of the QC analyses to lie inside 100 ± 15 % of
the nominal values.
Effect of plumbagin on CYP1A2 and CYP3A11 mRNA
expression
The liver sample isolated from each mouse was rinsed
with ice-cold, 0.9 % NaCl and total RNA was prepared
using TrizolTM reagent according to the manufacturer’s
protocol (Invitrogen, Karlsruhe, Germany). Briefly, the
sample was homogenized in TRIZOL reagent (1 mL) per
50–100 mg of tissue. The homogenized sample was incu-
bated at 25 °C for 5 min and chloroform (0.2 mL/1 mL of
TRIZOL reagent) was added. The sample was thoroughly
mixed and incubated at 25 °C for 3 min. Following centri-
fugation (12,000 × g for 15 min, 2–8 °C), the sample was
separated into a lower red phenol-chloroform phase, an
interphase, and a colorless upper aqueous phase. The
upper aqueous phase was transferred carefully into a fresh
tube and RNA was separated by mixing with 0.5 mL iso-
propyl alcohol and incubated at 15–30 °C for 10 min.
After centrifugation (12,000 × g for 10 min, 2–4 °C), the
precipitated RNA was washed with 75 % ethanol (1 mL)
and centrifuged at 7500 × g for 5 min (2–8 °C). The RNA
pellets were dried and dissolved in 20 μL DEPC-treated
water and the concentrations were determined using
NanoDrop Spectrophotometry (NanoDrop Technologies,
Wilmington, DE, USA). The RNA samples were treated
with RQ1 RNase-Free DNase according to the manufac-
turer’s protocol (Promega, Mannheim, Germany) to de-
grade both double-stranded and single-stranded DNA.
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The cDNA was prepared using the SuperScript™ III
Reverse Transcriptase according to the manufacturer’s
protocol (Invitrogen, Karlsruhe, Germany). Briefly, total
RNA (10 pg–5 μg) and 1 μL of 50 μM oligo(dT)20 were
incubated at 55 °C for 50 min. The reaction was inacti-
vated by heating at 70 °C for 15 min and chilled on ice
for 2 min. cDNA was synthesized in a total volume of
20 μL containing 5× First-Strand Buffer (250 mM Tris–
HCl (pH 8.3), 375 mM KCl, and 15 mM MgCl2), 0.1 M
DTT, 40 U RNaseOUT™ Recombinant RNase Inhibitor,
10 mM dNTPs, and 200 U Superscript III Reverse Tran-
scriptase Rnase H (Invitrogen, Thermo Fisher Scienyific,
NY, USA).
The forward and reverse primers for the selected genes
used in the study are shown in Table 2 [19]. The plat-
inum SYBRTM Green qPCR Supermix-UDG (Invitrgen,
Carsbad, CA, USA) was used for real-time PCR (RT-
PCR) analysis using iCycler IQ machine (BioRad Labora-
tories Inc., Hercules, CA, USA). The reaction mixture
(25 μL) consisted of 50 ng/μL cDNA, platinum SYBRTM
Green qPCR Supermix-UDG mixture, 10 μM forward
primer, 10 μM reverse primer, and sterile double distilled
water. The PCR cycles for CYP1A2, CYP3A11 and
GAPDH were as follows: denaturation at 95 °C for
10 min, followed by 40 cycles of amplification at 95 °C
for 15 s, and annealing at 60 °C for 1 min. Each RT-PCR
was performed in duplicate. Ct values (threshold cycle)
which is the intersection between an amplification and
threshold line was generated to reflect relative measure
of the concentration of target in the RT-PCR reaction.
The delta-delta Ct method was used to calculate
CYP1A2 or CYP3A11 gene expression level relative to
control and the housekeeping gene GAPDH was used
for normalization of CYP1A2 or CYP3A11 gene expres-
sion [19]. The delta-delta Ct calculation for the relative
quantification of target gene was as follow:
ΔCt 1ð Þ ¼ Ct CYP1A2 or CYP3A11ð Þ−Ct GAPDHð Þ½ 
ΔCt 2ð Þ ¼ ½Ct control for CYP1A2 or CYP3A11ð Þ
−Ct control for GAPDHð ÞΔΔCt
¼ ΔCt 1ð ÞΔCt 2ð ÞRelative expression
¼ 2ΔΔCt
where ΔCt (1) = delta Ct of unknown sample, ΔCt (2) =
delta Ct of control, CYP1A2 and CYP3A11 are target
genes, and GAPDH is a housekeeping gene.
Statistical analysis
Statistical analysis was performed using SPSS version
16.0 (SPSS Inc., CO, USA). Distribution of all variables
was assessed using Kolmogorov-Smirnov test for nor-
mality and results indicate non-normally distributed
data. All quantitative variables are presented as median
(interquartile range) for non-normally distributed data.
Comparison of difference in quantitative variables be-
tween two groups and more than two groups was per-
formed using independent Mann–Whitney U test and
Kruskal-Wallis test (followed by pair-wise comparison
by Mann–Whitney U test). Statistical significance level
was set at α = 0.05 for all tests.
Results
Toxicity testing
All rats survived following a single oral dose of 150 mg/
kg body weight plumbagin and 20 % Tween-80 (control).
There was no visible sign of toxicity, or any change in
water and food consumption and body weights of rats in
both groups during the 14 days of observation. At higher
doses (250 and 500 mg/kg body weight), plumbagin pro-
duced toxic signs and symptoms including anxiety, sali-
vation, exhibited chewing, and agitation. Three (3/6) and
all (6/6) of the animals in each group died, respectively.
Histopathological examination of various organs (liver,
kidney, heart, spleen, and lung) revealed no significant
change in size and morphology in all animals receiving
all dose levels of plumbagin. No gender-specific toxicity
was observed at all dose levels.
For subacute toxicity test, all rats survived following a
daily oral dose of 25 mg/kg body weight plumbagin and
20 % Tween-80 (control) for 28 days. There was no ab-
normality in behavior, sign of toxicity, nor changes in
water and food consumption, as well as body weights in
both groups during the 28 days observation period.
Histopathological examination of various organs (liver,
kidney, heart, spleen, and lung) revealed no significant
change in size and morphology in animals of both
group. There were no significant changes in blood
chemistry and hematology of rats in both groups
Table 2 Primer sequences used for determination of CYP1A2 and CYP3A11 mRNA expression
Gene Gene accession number Amplicon size (bp) Primer sequence Melt Temperature (°C)
CYP1A2 NM_009993 149 Forward: 5′-TGGTGGAATCGGTGGCTAAC-3′ 82.50
Reverse: 5′- GACCGGGAAGAAGTCCACTG-3′
CYP3A11 NM_007818 121 Forward: 5′- ACCTGGGTGCTCCTAGCAAT-3′ 80.50
Reverse: 5′- GCACAGTGCCTAAAAATGGCA-3′
GAPDH NM_001289726 136 Forward: 5′- GGAGAGTGTTTCCTCGTCCC-3′ 84.50
Reverse: 5′- ATGAAGGGGTCGTTGATGGC-3′
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(Table 3A and B). Toxic signs and symptoms including
anxiety, salivation, exhibited chewing and agitation were
observed in 2/6 and 6/6 rats following the doses of
50 and 100 mg/kg body weight, respectively. All rats
receiving 100 mg/kg body weight of plumbagin daily
for 28 days died within 6–10 days, while two rats re-
ceiving 50 mg/kg body weight dosing died within 12–
16 days. No rat died during dosing and after 28 days
of dosing. No gender-specific toxicity was observed at
all dose levels.
Pharmacokinetic investigation
Plumbagin was detected in the urine samples up to
4 days (96 h) of dosing in all rats following a single oral
dose of 100 mg/kg body weight of plumbagin. Median
(interquartile range) of plumbagin excreted during 0–24,
0–48, 72, and 0–96 h were 389 (42), 258 (99), 15 (9) and
1.8 (0.3) μg, respectively. Total recovery of plumbagin
during 0–96 h of dosing was only 3–5 %. The pharma-
cokinetic profile and parameters of plumbagin are pre-
sented in Fig. 1 and Table 4. Plumbagin was slowly
absorbed after the oral dose reaching maximal plasma
concentration at 5 h.
Modulatory effect of plumbagin on CYP450
Figure 2 shows median (interquartile range) concentra-
tions of paracetamol (CYP1A2-mediated phenacetin O-
deethylation) and oxidized nifedipine (CYP3A11-medi-
ated nifedipine oxidation) in liver microsomes prepared
from mice following treatment with oral plumbagin at
daily doses of 25, 12.5, and 6.25 mg/kg body weight and
Tween-80 (control group) for 28 days. There was no sig-
nificant change in the amounts of metabolites produced
by both enzymes, although CYP1A2 activity tended to
be reduced by plumbagin, particularly at the lowest dose
level of 6.25 mg/kg body weight. These modulatory ef-
fects on CYP1A2 and CYP3A11 activities correlated well
with the mRNA expression of both enzymes (Fig. 3).
Discussion
The toxicity of plumbagin in rats was investigated in
order to define the well tolerated dose of plumbagin for
pharmacokinetic investigation. Selection of rat rather
than mouse as a rodent species of choice is due to the
possibility to collect larger blood volume required for
quantitation of plumagin in plasma for pharmacokinetic
analysis. The maximum tolerated doses of plumbagin in
the acute and subacute toxicity testing were 150 (single
oral dose) and 25 (daily doses for 28 days) mg/kg body
weight, respectively. The 50 % lethal dose (LD50) of
plumbagin for the acute and subacute toxicity testing
were 250 and 50–100 mg/kg body weight, respectively.
The dose selected for the pharmacokinetic study was a
single oral dose of 100 mg/kg body weight, which is
lower than the maximal tolerated dose (150 mg/kg
body weight) to ensure that no rat died during the
study. There was no significant change in
hematological and blood biochemistry profiles of rats
treated with maximal tolerated daily dose of 25 mg/
kg for 28 days. In previous studies in mice however,
various types of toxicity of plumbagin were reported.
These included diarrhea, skin rashes, leukocytosis, in-
creased serum phosphatase levels [20], hepatotoxicity
[21, 22], and cardiotoxicity [23]. In a more recent
study in mice [24], hepatotoxicity of plumbagin
through unbalancing of the anti-oxidative system was
observed, i.e., marked increased plasma ALT and AST
levels, hepatic lipid peroxidation, and glutathione per-
oxidase activity; but decreased superoxide dismutase
and catalase activities. Furthermore, by virtue of its
similar chemical structure to vitamin K, plumbagin as
a component of Plumbago zeylanica, was also sus-
pected to affect blood hemostatis mechanisms. The
platelet adhesion and coagulation was significantly de-
creased in the treated rats (daily doses of 2 mg/kg
Table 3 Effects of plumbagin on (A) blood chemistry and (B)
hematological parameters in serum of rats after daily oral
administration at 25 mg/kg body weight for 28 days (3 males
and 3 females for each group). Data are presented as median
(interquartile range)
Parameter Control Plumbagin 25 mg/kg body
weight
(A)
Glucose (mg/dL) 248 (80) 230 (59)
BUN (mg/dL) 20.5 (6.5) 22.0 (7.5)
Creatinine (mg/dL) 0.50 (0.00) 0.50 (0.00)
Cholesterol (mg/dL) 68 (3) 73 (6)
Triglyceride (mg/dL) 106 (13) 110 (9)
AST (U/L) 100 (17) 101 (15)
ALT (U/L) 27 (10) 30 (11)
(B)
RBC (×106/μL) 8.27 (0.50) 8.16 (0.72)
Hemoglobin (g/dL) 14.9 (0.7) 14.4 (1.2)
Hematocrit (%) 47.9 (3.0) 47.8 (2.6)
WBC (×103/μL) 9.10 (0.80) 9.40 (0.65)
Neutrophils (×103/μL) 1.92 (0.11) 2.20 (0.63)
Eosinophils (×103/μL) 0.50 (1.00) 0.00 (1.00)
Lymphocytes (×103/
μL)
7.41 (0.28) 7.59 (0.31)






Blood morphology Normal Normal
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body weight) resulting in prolongation of bleeding
time [25]. The discrepancies in such toxicity profiles
observed in various studies could suggest species-
specific toxicity of plumbagin and the extract of
Plumbago spp. In addition, the dose level and dur-
ation given in the current study (25 mg/kg body
weight for 28 days) may not be high enough to pro-
duce such toxicity. The maximal tolerated doses of
plumbagin in the subacute toxicity testing in rats re-
ported in the current study is similar to that reported
in mice in our previous study (25 mg/kg body weight
for 14 days), but the maximal tolerated dose in the
acute toxicity testing in mice is relatively lower
(100 mg/kg body weight). Results of both studies in-
dicate low toxicity of plumbagin in both animal spe-
cies. Nevertheless, hepatotoxicity as well as other
toxic effects of plumbagin should be of great concern
for future development of plumbagin as medicines.
Dose ranging study to obtain information on safety
window of effective and toxic doses should be
carefully investigated. It is noted however that the ra-
tios of plasma AST/ALT (>3:1) in both the control
and treated rats were higher than the normal value
reported in rats (2:1). Previous animal studies in
Thailand using Wistar or Sprague Dawley rats (pro-
vided by the National Laboratory Animal Center of
Thailand: NLACT) also reported the ratios of greater
than 3:1 [26, 27]. Histopathological examination did
not reveal any abnormality both in the control and
treated groups. Plasma glucose level was also found
to be relatively high (median values of 248 and
230 mg/dL in the control and treated rats, respect-
ively) comparing with the normal range reported in
Wistar rats (70–100 mg/dL) [28]. This hyperglycemic
condition could be due to the influence of the volatile
anesthetics isoflurane in impairing glucose-induced in-
sulin release [29].
The pharmacokinetics study in Wistar rats revealed
the median elimination half-life (t1/2), and mean resi-
dence time (MRT) of the plumbagin of about 9.6 and
5.0 h, respectively. These values were relatively short
compared with the previously reported mean values of
17 and 22 h, respectively, in conscious freely moving
Sprague–Dawley rats using liquid chromatography/tan-
dem mass spectrometry [13]. The time to reach max-
imum blood concentration (tmax) was about two times
longer (5.0 vs 2.5 h). It was unexpected that only the
species difference of rats used in both studies (Wistar vs
Sprague–Dawley rats) could have had significant impact
on the pharmacokinetics of plumbagin given by oral
dosing. Although permeability across human intestinal
membrane was reported to be moderate with no influ-
ence of efflux protein, oral bioavailability of plumbagin
was shown to be relatively low (39 %) due to its limited
biopharmaceutical properties such as high lipophilicity
Fig. 1 Median (interquartile range) plasma concentration–time profile of plumagin in male Wistar rats (n = 4) after a single oral administration of
100 mg/kg body weight of plumbagin
Table 4 The pharmacokinetic parameters of plumbagin after
oral administration of 100 mg/kg body weight of plumbagin to
healthy male Wistar rats [median (interquartile range), n = 4]
Parameter Plumbagin
t1/2 (h) 9.63 (3.04)
tmax (h) 5.0 (0.0)
Cmax (μg/mL) 0.46 (0.15)
AUC0-48h (μg h/mL) 6.51 (1.16)
AUC0−∞ (μg h/mL) 6.71 (1.41)
MRT (h) 12.88 (2.49)
Vd/F (L/mg dose/kg body weight) 0.0022 (0.00)
CL/F (L/h/mg dose/kg body weight) 0.15 (0.3)
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(log P 3.04) and insolubility in water [13]. Plumbagin
was rapidly cleared from blood circulation and was only
detected in systemic circulation up to 48 h. The time
period until complete elimination in urine was 96 h,
with extremely low recovery (3–5 % of the administered
dose). This observation indirectly supports results from
the previous study in mice using SPECT/CT imaging
system which suggests hepatobiliary and pulmonary, ra-
ther than urinary excretion, as major routes of elimin-
ation of plumbagin [8]. 99mTc-plumbagin complex was
shown to be rapidly and extensively accumulated in
livers and lungs of both healthy and infected mice as
early as 5 min after dosing. Results of the in vitro study
using human liver microsomes containing drug metabol-
izing enzymes supported the role of liver in the biotrans-
formation of plumbagin, which well explained the high
accumulation of 99mTc-plumbagin complex in this organ
[8]. Plumbagin is a volatile compound which is likely to
be excreted by pulmonary route through exhaled air
[25]. The pharmacokinetic profiles of plumbagin ob-
served in this and other studies [13, 30] suggest that low
systemic exposure might be a limiting pharmacokinetic
factor that leads to inadequate drug concentration for
antimalarial activity in animal models. This low systemic
exposure may strongly affect potential development of
plumbagin as an oral formulation. Various approaches
have been applied to improve the oral bioavailability of
plumbagin. These include preparation of liposomal for-
mulation [31], and chitosan-based microspheres [30].
CYP450 represents a large family of proteins involved in
the metabolism of drugs and other xenobiotics as well as
endogenous compounds. As the major drug metabolizing
enzymes in human liver, interactions between phytochem-
icals in herbal medicines and CYP450 are now well
Fig. 2 CYP1A2- and CYP3A11-mediated metabolism (generation of paracetamol and oxidized nifedipine, respectively) in mouse liver microsomes
from the treated (induced by plumbagin for 28 days) and the control groups. Data are expressed as median (interquartile range) from 3
male mice
Fig. 3 CYP1A2 and 3A11mRNA expression levels in mouse liver cells treated with 6.25, 12.5 and 25 mg/kg body weight for 28 days of
plumbagin) and control groups. GAPDH was used as an internal control. CYP1A2 and 3A11mRNA expression levels were quantified by RT-PCR
analysis in relation to GAPDH. Data are expressed as median (interquartile range) from 3 male mice
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recognized because of their potential clinical and toxico-
logical implications. The phytochemicals could act as sub-
strates, inhibitors, or inducers of the CYP450 isoforms,
which can lead to pharmacokinetic interactions with the
co-administered drugs metabolized by the same CYP450
isoform [32, 33]. Various CYP450 isoforms including
CYP1A2, CYP2A6, CYP2C, CYP2D6, CYP2E1, and
CYP3A are differentially expressed in human liver (13, 4,
20, 2, 7 and 30 %, respectively) [34]. Inhibition of
CYP450-mediated metabolism of the substrate drugs may
result in toxic drug concentrations. On the other hand, in-
duction of CYP450-mediated metabolism of the substrate
drugs may result in inadequate therapeutic drug concentra-
tions. Inhibition and induction of CYP450 enzymes by drugs
and food or supplement sources is well documented [35,
36]. Our previous studies [9, 10] provide evidence for the in-
hibitory effect of plumbagin and P. indica Linn. on the three
major hepatic CYP450 isoforms, i.e., CYP1A2, CYP3A4, and
notably CYP2C19 (mean IC50 of 12.95 μg/mL vs. 1.39 μM,
6.43 μg/mL vs. 2.37 μM, and 4.71 μg/mL vs. 0.78 μM, re-
spectively). In this study, plumbagin was not found to in-
duce or inhibit the mRNA expression and enzyme activities
of CYP1A2 and CYP3A11, although a trend of reduction of
both mRNA expression and enzyme activity was observed
with CYP3A11. Since the activities of both enzymes corre-
lated well with their mRNA expression, this suggests that
the changes in activities of both enzymes were results of re-
duced mRNA expression of both enzymes rather than the
direct interference with the enzyme activities.
CYP1A2 is known to play a major role in the metabolism
of pre-carcinogens and inhibitory effect of plumbagin to
this CYP450 isoform may contribute only minor interaction
with the co-administered drugs. On the other hand, this in-
hibitory effect would be expected to result in protection
against cancers [37]. Mouse was selected as a rodent spe-
cies for investigation of modulatory effect of plumbagin on
CYP1A2 and CYP3A11. The major reason is that func-
tional counterparts of almost all human genes exist within
the murine genome. One-hundred and two and 57 putative
functional CYP450 genes have been reported in mice and
humans, respectively. Thirty-six orthologous pairs of
CYP450 genes have been identified as having the potential
for similar or identical functions in both mice and humans
[38]. Human CYP3A4 and the murine homolog CYP3A11
are the major CYP450 regulated by pregnane X receptor.
Although mouse CYP3A11 was identified to be the most
similar human CYP3A subfamily with respect to catalytic
activity [39], differences in inducibility and catalytic activity
are possible. Since this CYP3A4 is the most important
CYP450 isoforms with respect to drug metabolism in
humans, extrapolating metabolism data from mice directly
to humans should be performed with caution. With respect
to CYP3A1A2, existing information provided strong sup-
port for the value and relevance of mouse CYP1A2-
dependent metabolism to the corresponding metabolism in
humans [40] in terms of catalytic activities and inhibitory
profiles by selective inhibitor (furafylline).
Conclusion
Plumbagin produced satisfactory toxicity profile in acute
and subacute toxicity tests following oral dose adminis-
tration in rats of both genders. Pharmacokinetics of
plumbagin of being delayed absorption and short resi-
dence time in plasma could be the key factor contribut-
ing to the observed weak antimalarial activity in vivo.
Plumbagin did not significantly modulate mRNA expres-
sion and thus, enzyme activities of both CYP1A2 and
CYP3A11 in mouse livers. Therefore, potential interac-
tions with co-administered drugs that are metabolized
by both enzymes are unlikely. Further development of
plumbagin for clinical uses in malaria and other diseases
should be focused on modification of pharmaceutical
formulation to improve pharmacokinetic properties. In
addition, dose ranging study in animal models should be
performed to obtain information on safety window of ef-
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